0001104659-20-022513.txt : 20200218 0001104659-20-022513.hdr.sgml : 20200218 20200218190741 ACCESSION NUMBER: 0001104659-20-022513 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200213 FILED AS OF DATE: 20200218 DATE AS OF CHANGE: 20200218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ITRI LORETTTA M CENTRAL INDEX KEY: 0001137918 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 20627029 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 3 1 a3.xml 3 X0206 3 2020-02-13 0 0000722830 IMMUNOMEDICS INC IMMU 0001137918 ITRI LORETTTA M C/O IMMUNOMEDICS, INC. 300 THE AMERICAN ROAD MORRIS PLAINS NJ 07950 0 1 0 0 Chief Medical Officer Common Stock, par value $0.01 per share 15000 D Stock Option (right to buy) 12.48 2029-06-11 Common Stock, par value $0.01 per share 20000 D Stock Option (right to buy) 14.35 2029-09-26 Common Stock, par value $0.01 per share 50000 D The Reporting Person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (as amended, the "Plan"). The stock options vest upon the earlier of (i) the Issuer's receipt of approval from the U.S. Food and Drug Administration ("FDA") of the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act (the "BLA"), (ii) May 6, 2020, and (iii) a Change in Control (as defined in the Plan). The Reporting Person was granted stock options pursuant to the Issuer's Plan. The stock options vest upon the earlier of (i) the Issuer's receipt of approval from the FDA of the Issuer's BLA, (ii) December 31, 2020, and (iii) a Change in Control (as defined in the Plan). Exhibit 24 - Power of Attorney By: /s/ Jared Freedberg, as attorney-in fact for Loretta Itri 2020-02-18 EX-24 2 ex-24.htm EX-24

Exhibit 24

 

LORETTA ITRI (the “Filer”)

LIMITED POWER OF ATTORNEY

 

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Jared Freedberg, Scott Cowan, and Brian Tribuna, subject to the expiration of this Limited Power of Attorney as set forth below, and each of them signing singly, and with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

 

(1)         execute for and on behalf of the undersigned, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID and the Form ID Confirming Statement, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings of a Forms 3, 4, and 5  with the SEC required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) for the undersigned;

 

(2)         Execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act, and the rules thereunder;

 

(3)         take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Immunomedics, Inc., a Delaware corporation (the “Company”), assuming, any responsibilities of the undersigned to comply with Section 16(a) of the Exchange Act, or any other law, rule or regulation whatsoever.

 

This Limited Power of Attorney shall remain in full force and effect until the earlier of (i) the time that the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, and (iii) the revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of February 13, 2020.

 

By:

/s/ Loretta Itri

 

Name: Loretta Itri